Clinical Trial Detail

NCT ID NCT03049618
Title Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Southern California
Indications

lung non-small cell carcinoma

head and neck squamous cell carcinoma

Therapies

Pembrolizumab + sEphB4-HSA

Age Groups: adult senior

No variant requirements are available.